A Double-blinded, Placebo-controlled Pilot Study of Dimethyl Fumarate (DMF) in Pulmonary Arterial Hypertension (PAH) Associated With Systemic Sclerosis (SSc-PAH): The Effect of DMF on Clinical Disease and Biomarkers of Oxidative Stress.

Trial Profile

A Double-blinded, Placebo-controlled Pilot Study of Dimethyl Fumarate (DMF) in Pulmonary Arterial Hypertension (PAH) Associated With Systemic Sclerosis (SSc-PAH): The Effect of DMF on Clinical Disease and Biomarkers of Oxidative Stress.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis; Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
    • 03 Jan 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top